PAH: The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.
Study Details
Study Description
Brief Summary
Pulmonary arterial hypertension (PAH) is a chronic disease characterized by an elevation in pulmonary artery pressures and pulmonary vascular resistance. The condition most often is rarely detected, and patients frequently suffer symptoms for several years before being appropriately diagnosed. Patients with PH suffer from several symptoms, such as exertional dyspnea, fatigue, weakness, chest pain, fainting…et al. Pulmonary hypertension is an incurable and progressive disease with complex symptoms and treatments. Patients must learn to deal with their unpredictable future and manage the complex treatments associated with severe adverse effects and need significant changes in lifestyle.
Therefore, it is important to assist patients to develop the ability of symptom management.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Web-based health care program We aim to develop a PAH web-based health care program, and to evaluate the effects of this program on ameliorating social support, self-care ability and active tolerance, and improving symptom distress, anxiety, depression and quality of life in patients with PAH. |
Other: Web-based health care program
According to the participants' feedback and recommends, we will modify this program to make it more suitable.
In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH.
|
| No Intervention: Usual care usual care |
Outcome Measures
Primary Outcome Measures
- Pulmonary Arterial Hypertension Symptom [Change from Baseline pulmonary Arterial Hypertension Symptom at six months]
Pulmonary Arterial Hypertension Symptom Interference Scale, PAHSS, The 10-point Likert scale higher scores mean a worse outcome.
Secondary Outcome Measures
- Social support [Change from Baseline social support at six months]
Multidimensional Scale of Perceived Social Support, (MSPSS). The 7-point Likert scale higher scores mean a better outcome.This instrument is 12 questions long and has been widely used and well validated.
- Activity ability [Change from Baseline activity ability at six months]
6 Minute walk test, 6MWD
- Pulmonary Hypertension Quality of life [Change from Baseline quality of life at six months]
The Cambridge Pulmonary Hypertension Outcome Review, (CAMPHOR). The 5-point Likert scale higher scores mean a better outcome.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least 20 years old, diagnosed by clinical specialists as patients with pulmonary hypertension (Group1 and Group 4)
-
Clear consciousness, able to communicate in Mandarin and Taiwanese, with normal hearing
-
Those who have internet or mobile internet at home
-
Adults without mental illness
-
No alcohol or drug abusers.
Exclusion Criteria:
- critical disease
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Tri-Service General Hospital | Taipei, Taiwan | Taipei | Taiwan | 114 |
Sponsors and Collaborators
- National Defense Medical Center, Taiwan
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NDMC